<DOC>
	<DOCNO>NCT00231413</DOCNO>
	<brief_summary>Human Papilloma virus ( HPV ) viruses cause infection skin genitals men woman . Several type HPV infection transmit sexual activity , woman , infect cervix ( part uterus womb ) . This infection , persists , lead long period time cancer cervix woman . In collaboration MedImmune Inc. , GlaxoSmithKline Biologicals develop HPV vaccine oncogenic type HPV-16 HPV-18 formulate adjuvant AS04 . GSK Biologicals also evaluate novel HPV vaccine formulations.This study evaluate immunogenicity safety novel GSK Biologicals HPV vaccine woman 18-25 year age study start . Approximately 376 study subject receive novel HPV vaccine control vaccine administer intramuscularly accord 0-1-6 month schedule</brief_summary>
	<brief_title>Human Papilloma Virus Vaccine Immunogenicity Safety Trial Young Adult Women With GSK Bio 's Novel HPV Vaccine .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>A woman , include , 18 25 year age time first vaccination . Written inform consent subject prior enrolment . Subject must free obvious health problem . Subject must nonchildbearing potential 6 lifetime sexual partner . Pregnant breastfeeding . A woman plan become pregnant planning discontinue contraceptive precaution approximately first nine month study ( Month 08 ) . Known acute chronic , clinically significant pulmonary , cardiovascular , neurologic , hepatic renal functional abnormality . History chronic condition ( ) require treatment cancer , chronic hepatitis kidney disease ( ) , diabetes , autoimmune disease . Previous vaccination human papillomavirus ( HPV )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>